Cogent Biosciences, Inc. Purchase Obligation
Cogent Biosciences, Inc. (COGT) had Purchase Obligation of $300.00 thousand as of 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Notes
us-gaap:PurchaseObligation · last filed 2020-05-11
- 2020-03-31: Purchase Obligation $300.00K.
- 2019-12-31: Purchase Obligation $1.00M.
- 2019-09-30: Purchase Obligation $1.60M.
- 2019-06-30: Purchase Obligation $2.40M.
| Period end | Purchase Obligation |
|---|---|
| 2020-03-31 | $300.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.00M 10-K · filed 2020-03-26 |
| 2019-09-30 | $1.60M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $2.40M 10-Q · filed 2019-08-12 |
| 2019-03-31 | $3.60M 10-Q · filed 2019-05-13 |
| 2018-12-31 | $1.50M 10-K · filed 2019-03-28 |
| 2018-09-30 | $1.50M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $1.70M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $900.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |